DHR stock verdict - Avoid
DHR
Danaher Corporation
AVOIDHealthcare
$191.50
Overvalued (≥ exit)
$191.50
Heavy$66.70Buy$88.93Fair$111.16Exit$133.39
FUNDAMENTAL56
TECHNICAL47
TRUST SCORE
100High
confidence in this read — data completeness, earnings quality & coverage
Neutral · EMA20 192.26 · EMA50 189.0 · EMA200 197.42 · RSI 50.3 · MACD below signal
PROS
- TTM EPS grew 19.6% year-over-year
- Converts 22% of revenue into free cash flow
- High gross margin of 59% (3-yr avg)
CONS
- Trades above the model's exit level ($133.39) — overvalued on this framework
- Expensive on trailing earnings (P/E 34.0×)
- Company has a low return on equity of 7.6% (TTM)
- Revenue declined 2.5%/yr on average over the last 3 years
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 178% of net income — profit is backed by real cash
✓Low accruals — reported profit tracks the cash actually generated
✓Receivables growing in line with sales
SECTOR PEERS
Analysis as of 2026-07-27 · price live, fundamentals from latest filings
FAQ
Why is DHR rated Avoid?
DHR (Danaher Corporation) is rated Avoid because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Overvalued (≥ exit). TTM EPS grew 19.6% year-over-year and Converts 22% of revenue into free cash flow
Is DHR overvalued right now?
DHR is trading at $191.50 versus an estimated fair value of $111.16. That puts the stock in avoid territory on this framework. Trades above the model's exit level ($133.39) — overvalued on this framework and Expensive on trailing earnings (P/E 34.0×)
What should I watch before acting on DHR?
Watch the trust score of 100, the earnings-quality checks, and any red flags. Trades above the model's exit level ($133.39) — overvalued on this framework and Expensive on trailing earnings (P/E 34.0×)